Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

SSTR2a Is a Useful Diagnostic Marker for Follicular Dendritic Cells and Their Related Tumors.

Tao LL, Huang YH, Chen YL, Yu GY, Yin WH.

Am J Surg Pathol. 2019 Mar;43(3):374-381. doi: 10.1097/PAS.0000000000001205.

PMID:
30585825
2.

Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.

Terlević R, Perić Balja M, Tomas D, Skenderi F, Krušlin B, Vranic S, Demirović A.

Ann Diagn Pathol. 2019 Feb;38:62-66. doi: 10.1016/j.anndiagpath.2018.11.002. Epub 2018 Nov 20.

PMID:
30476894
3.

SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.

de Vries LH, Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, Schepers A, Bonenkamp HJ, van Engen-van Grunsven IACH, Kruijff S, van Hemel BM, Links TP, Nieveen van Dijkum EJM, van Eeden S, Valk GD, Borel Rinkes IHM, Vriens MR.

Endocrine. 2018 Dec;62(3):639-647. doi: 10.1007/s12020-018-1706-1. Epub 2018 Aug 20.

4.

Meningothelial-like Nodules of the Lung Show SSTR2a Immunohistochemical Staining.

Richardson TE, Butt YM, Torrealba JR, Gokaslan ST.

Arch Pathol Lab Med. 2018 Jul;142(7):781-782. doi: 10.5858/arpa.2018-0079-LE. No abstract available.

PMID:
29939782
5.

Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas.

Fuchs TL, Sioson L, Sheen A, Clarkson A, Gill AJ.

Pathology. 2018 Jun;50(4):472-474. doi: 10.1016/j.pathol.2017.10.024. Epub 2018 May 3. No abstract available.

PMID:
29731144
6.

Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma.

Anis SE, Lotfalla M, Zain M, Kamel NN, Soliman AA.

Open Access Maced J Med Sci. 2018 Jan 29;6(2):248-253. doi: 10.3889/oamjms.2018.062. eCollection 2018 Feb 15.

7.

In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.

Charoenpitakchai M, Liu E, Zhao Z, Koyama T, Huh WJ, Berlin J, Hande K, Walker R, Shi C.

Virchows Arch. 2017 May;470(5):545-552. doi: 10.1007/s00428-017-2093-3. Epub 2017 Feb 17.

8.

Association between methylation of SHP-1 isoform I and SSTR2A promoter regions with breast and prostate carcinoma development.

Tiscornia MM, González HS, Lorenzati MA, Zapata PD.

Cancer Invest. 2015 Mar;33(3):61-9. doi: 10.3109/07357907.2014.1001892. Epub 2015 Jan 30.

PMID:
25635370
9.

Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.

Elston MS, Meyer-Rochow GY, Conaglen HM, Clarkson A, Clifton-Bligh RJ, Conaglen JV, Gill AJ.

Hum Pathol. 2015 Mar;46(3):390-6. doi: 10.1016/j.humpath.2014.11.012. Epub 2014 Dec 2.

PMID:
25554089
10.

Use of immunohistochemistry for SSTR2A to support a diagnosis of phosphaturic mesenchymal tumour.

Clugston E, Gill AC, Graf N, Bonar F, Gill AJ.

Pathology. 2015 Feb;47(2):173-5. doi: 10.1097/PAT.0000000000000221. No abstract available.

PMID:
25551311
11.

Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies.

Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G.

Hum Pathol. 2014 Jan;45(1):71-7. doi: 10.1016/j.humpath.2013.08.007. Epub 2013 Oct 31.

PMID:
24182563
12.

Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.

Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9. doi: 10.1210/jc.2013-2145. Epub 2013 Oct 3.

PMID:
24092823
13.

Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, Ranchere-Vince D, Decouvelaere AV, de la Fouchardiere A, Gill AJ.

Hum Pathol. 2013 Dec;44(12):2711-8. doi: 10.1016/j.humpath.2013.07.016. Epub 2013 Sep 20.

PMID:
24060005
14.

Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors.

Lécolle K, Bégard S, Caillierez R, Demeyer D, Grellier E, Loyens A, Csaba Z, Beauvillain JC, D'Halluin JC, Baroncini M, Lejeune JP, Sharif A, Prévot V, Dournaud P, Buée L, Colin M.

Gene Ther. 2013 Mar;20(3):283-97. doi: 10.1038/gt.2012.39. Epub 2012 May 17.

PMID:
22592599
15.

Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma.

Romiti A, Di Rocco R, Milione M, Ruco L, Ziparo V, Zullo A, Duranti E, Sarcina I, Barucca V, D'Antonio C, Marchetti P.

Anticancer Res. 2012 Jan;32(1):115-9.

PMID:
22213295
16.

Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.

Muscarella LA, D'Alessandro V, la Torre A, Copetti M, De Cata A, Parrella P, Sperandeo M, Pellegrini F, Frusciante V, Maiello E, Merla G, Fazio VM, Vendemiale G.

Cell Oncol (Dordr). 2011 Oct;34(5):435-41. doi: 10.1007/s13402-011-0025-9. Epub 2011 Apr 19.

PMID:
21503779
17.
18.

[Expression and their clinical significance of SSTR2A, SSTR5 and EGFR in non-small cell lung cancer].

Liu X, Tian H, Wang X, Ding J.

Zhongguo Fei Ai Za Zhi. 2007 Feb 20;10(1):14-9. doi: 10.3779/j.issn.1009-3419.2007.01.04. Chinese.

19.

[Production and preliminary characteristics of polyclonal antibodies specific to SSTR2A and SSTR5 receptors in the pituitary gland].

Bartoszewicz Z, Baran A, Makowska AM, Matyja E, Bar-Andziak E.

Endokrynol Pol. 2005 Jan-Feb;56(1):8-13. Polish.

PMID:
16335667

Supplemental Content

Support Center